AstraZeneca PLC
Financials
Valuation Metrics
AstraZeneca PLC's Market Cap is $257.51B. At end of 2025 it was $141.02B. Ranked #54 of 3,121 in US market (top 2%), #32 of 1,658 on NYSE (top 2%), #6 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 2%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $257.51B | US#54/3,121 Sec#6/266 |
| Revenue | $61.37B | US#103/3,121 Sec#6/266 |
| Net Income | $10.45B | US#62/3,121 Sec#5/266 |
| Total Assets | $115.70B | US#154/3,121 Sec#8/266 |
| Net Assets | $50.24B | US#86/3,121 Sec#4/266 |
| Employees | 96,100 | US#119/3,121 Sec#2/266 |
| Value | ||
| P/E | 24.65x | US#1,392/3,121 Sec#39/266 |
| P/B | 5.13x | US#2,243/3,121 Sec#144/266 |
| PEG | 0.95x | US#829/3,121 Sec#25/266 |
| P/S | 4.20x | US#2,130/3,121 Sec#65/266 |
| EV/EBITDA | 13.78x | US#1,389/3,121 Sec#37/266 |
| FCF Yield | 3.39% | US#1,752/3,121 Sec#54/266 |
| Profitability | ||
| ROE | 20.79% | US#547/3,121 Sec#27/266 |
| ROA | 9.03% | US#553/3,121 Sec#37/266 |
| Op. Margin | 22.77% | US#779/3,121 Sec#36/266 |
| Revenue Growth | 8.61% | US#1,414/3,121 Sec#105/266 |
| Earnings Growth | 25.93% | US#760/3,121 Sec#28/266 |
| Financial Health | ||
| Debt Ratio | 130.16% | US#1,352/3,121 Sec#178/266 |
| Total Debt | $32.20B | US#150/3,121 Sec#9/266 |
| FCF | $8.74B | US#100/3,121 Sec#12/266 |
| Cash | $4.89B | US#202/3,121 Sec#12/266 |
| Current Ratio | 0.89x | US#2,404/3,121 Sec#260/266 |
| Net Debt/EBITDA | 1.32x | US#1,096/3,121 Sec#50/266 |
| Dividend | ||
| Div. Yield | 1.91% | US#979/3,121 Sec#18/266 |
| Div. Growth | 9.78% | US#531/3,121 Sec#6/266 |
| Performance | ||
| 1Y Return | 8.85% | US#1,522/3,121 Sec#173/266 |
| 1M Return | 0.66% | US#577/3,121 Sec#62/266 |
| From 52W High | -21.12% | US#1,579/3,121 Sec#118/266 |
| 1Y MDD | -25.41% | US#1,080/3,121 Sec#56/266 |
| Trading | ||
| Volume | 2,557,489 shares | US#550/3,121 Sec#47/266 |
| Trading Value | $426M | US#173/3,121 Sec#8/266 |
| Per Share | ||
| EPS | $6.74 | US#489/3,121 Sec#14/266 |
| BPS | $32.39 | US#828/3,121 Sec#17/266 |
Company Info
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.